Strides Pharma Science Limited (STAR.BO)
INR 615.1
(5.32%)
INR 615.1
(5.32%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 40.51 Billion INR | 12.29% |
| 2022 | 36.07 Billion INR | 19.38% |
| 2021 | 30.22 Billion INR | -7.05% |
| 2020 | 32.51 Billion INR | 22.37% |
| 2019 | 26.56 Billion INR | 26.01% |
| 2018 | 21.08 Billion INR | -24.61% |
| 2017 | 27.96 Billion INR | 5.28% |
| 2016 | 26.56 Billion INR | -3.45% |
| 2015 | 27.51 Billion INR | 143.15% |
| 2014 | 11.31 Billion INR | 5.47% |
| 2013 | 10.72 Billion INR | 20.27% |
| 2012 | 8.91 Billion INR | -64.49% |
| 2011 | 25.11 Billion INR | 48.1% |
| 2010 | 16.95 Billion INR | 29.97% |
| 2009 | 13.04 Billion INR | 27.88% |
| 2008 | 10.2 Billion INR | 37.1% |
| 2007 | 7.44 Billion INR | 0.17% |
| 2006 | 7.42 Billion INR | 41.87% |
| 2005 | 5.23 Billion INR | 16.76% |
| 2004 | 4.48 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 12.01 Billion INR | 10.45% |
| 2024 Q1 | 10.87 Billion INR | 0.32% |
| 2023 FY | 40.51 Billion INR | 12.29% |
| 2023 Q3 | 10.37 Billion INR | 3.83% |
| 2023 Q2 | 9.99 Billion INR | 7.47% |
| 2023 Q4 | 10.84 Billion INR | 4.47% |
| 2023 Q1 | 9.29 Billion INR | 2.69% |
| 2022 Q3 | 8.64 Billion INR | -3.6% |
| 2022 Q4 | 9.05 Billion INR | 4.72% |
| 2022 Q1 | 9.4 Billion INR | 14.95% |
| 2022 FY | 36.07 Billion INR | 19.38% |
| 2022 Q2 | 8.97 Billion INR | -4.57% |
| 2021 Q3 | 7.94 Billion INR | 10.11% |
| 2021 Q1 | 6.88 Billion INR | -18.42% |
| 2021 Q2 | 7.21 Billion INR | 4.81% |
| 2021 Q4 | 8.17 Billion INR | 2.95% |
| 2021 FY | 30.22 Billion INR | -7.05% |
| 2020 Q3 | 8.32 Billion INR | 4.85% |
| 2020 FY | 32.51 Billion INR | 22.37% |
| 2020 Q2 | 7.93 Billion INR | 1.5% |
| 2020 Q4 | 8.43 Billion INR | 1.41% |
| 2020 Q1 | 7.81 Billion INR | 49.36% |
| 2019 Q2 | 7.15 Billion INR | 4.27% |
| 2019 Q4 | 5.23 Billion INR | -28.54% |
| 2019 Q1 | 6.85 Billion INR | -8.95% |
| 2019 FY | 26.56 Billion INR | 26.01% |
| 2019 Q3 | 7.32 Billion INR | 2.43% |
| 2018 Q3 | 5.69 Billion INR | 9.68% |
| 2018 FY | 21.08 Billion INR | -24.61% |
| 2018 Q4 | 7.53 Billion INR | 32.17% |
| 2018 Q2 | 5.19 Billion INR | 9.93% |
| 2018 Q1 | 4.72 Billion INR | -28.83% |
| 2017 Q2 | 7.68 Billion INR | 16.86% |
| 2017 Q3 | 7.48 Billion INR | -2.59% |
| 2017 Q4 | 6.64 Billion INR | -11.3% |
| 2017 Q1 | 6.57 Billion INR | -2.86% |
| 2017 FY | 27.96 Billion INR | 5.28% |
| 2016 Q2 | 8.71 Billion INR | 10.44% |
| 2016 FY | 26.56 Billion INR | -3.45% |
| 2016 Q3 | 7.29 Billion INR | -16.31% |
| 2016 Q4 | 6.77 Billion INR | -7.21% |
| 2016 Q1 | 7.89 Billion INR | -14.58% |
| 2015 FY | 27.51 Billion INR | 143.15% |
| 2015 Q2 | 6.76 Billion INR | 15.88% |
| 2015 Q4 | 9.24 Billion INR | 10.88% |
| 2015 Q3 | 8.33 Billion INR | 23.18% |
| 2015 Q1 | 5.84 Billion INR | 87.57% |
| 2014 Q3 | 3.14 Billion INR | 18.53% |
| 2014 FY | 11.31 Billion INR | 5.47% |
| 2014 Q2 | 2.65 Billion INR | 10.03% |
| 2014 Q1 | 2.41 Billion INR | 0.0% |
| 2014 Q4 | 3.11 Billion INR | -0.96% |
| 2013 FY | 10.72 Billion INR | 20.27% |
| 2012 FY | 8.91 Billion INR | -64.49% |
| 2011 FY | 25.11 Billion INR | 48.1% |
| 2010 FY | 16.95 Billion INR | 29.97% |
| 2009 FY | 13.04 Billion INR | 27.88% |
| 2008 FY | 10.2 Billion INR | 37.1% |
| 2007 FY | 7.44 Billion INR | 0.17% |
| 2006 FY | 7.42 Billion INR | 41.87% |
| 2005 FY | 5.23 Billion INR | 16.76% |
| 2004 FY | 4.48 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 91.647% |
| NATCO Pharma Limited | 40.02 Billion INR | -1.227% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -285.325% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -1462.668% |
| Achyut Healthcare Limited | 61.36 Million INR | -65912.547% |
| Ajanta Pharma Limited | 42.08 Billion INR | 3.744% |
| Alkem Laboratories Limited | 126.67 Billion INR | 68.02% |
| Alpa Laboratories Limited | 1.08 Billion INR | -3625.548% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 33.72% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -212.7% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 85.887% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -755.718% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -425.953% |
| Brooks Laboratories Limited | 794.86 Million INR | -4996.645% |
| Divi's Laboratories Limited | 78.45 Billion INR | 48.36% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 85.488% |
| Eris Lifesciences Limited | 20.09 Billion INR | -101.634% |
| FDC Limited | 19.42 Billion INR | -108.504% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 65.707% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -77.431% |
| Granules India Limited | 45.06 Billion INR | 10.102% |
| Gufic Biosciences Limited | 8.06 Billion INR | -402.206% |
| Hester Biosciences Limited | 3.04 Billion INR | -1230.217% |
| Indoco Remedies Limited | 17.89 Billion INR | -126.389% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -216.272% |
| Ipca Laboratories Limited | 76.22 Billion INR | 46.852% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -1841.105% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -7934.517% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -3782.804% |
| Laurus Labs Limited | 50.01 Billion INR | 19.007% |
| Lupin Limited | 200.1 Billion INR | 79.755% |
| Mankind Pharma Limited | 103.34 Billion INR | 60.801% |
| Medicamen Biotech Limited | 1.79 Billion INR | -2159.333% |
| Medico Remedies Limited | 1.44 Billion INR | -2695.407% |
| Megasoft Limited | 373.95 Million INR | -10733.244% |
| Piramal Pharma Limited | 81.71 Billion INR | 50.422% |
| RPG Life Sciences Limited | 5.82 Billion INR | -596.01% |
| Sigachi Industries Limited | 3.98 Billion INR | -915.431% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -5262.51% |
| Unichem Laboratories Limited | 16.57 Billion INR | -144.424% |
| Wanbury Limited | 5.75 Billion INR | -603.748% |
| Windlas Biotech Limited | 6.3 Billion INR | -542.061% |
| ZIM Laboratories Limited | 3.67 Billion INR | -1002.573% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 78.702% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -251.886% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -861.736% |
| Bal Pharma Limited | 3.39 Billion INR | -1094.248% |
| Venus Remedies Limited | 5.91 Billion INR | -584.948% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -123.14% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -140.553% |
| Shilpa Medicare Limited | 11.51 Billion INR | -251.781% |
| Aarti Drugs Limited | 25.28 Billion INR | -60.214% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | -91.185% |
| Suven Life Sciences Limited | 116.92 Million INR | -34546.016% |
| Ind-Swift Limited | 5.02 Billion INR | -706.245% |
| Valiant Laboratories Limited | 1.82 Billion INR | -2125.193% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | -16.272% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -227.128% |
| Themis Medicare Limited | 3.81 Billion INR | -961.168% |
| Hikal Limited | 17.84 Billion INR | -127.005% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 61.801% |
| Sequent Scientific Limited | 13.69 Billion INR | -195.761% |
| Novartis India Limited | 3.35 Billion INR | -1109.038% |
| Wockhardt Limited | 27.89 Billion INR | -45.254% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 39.562% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -10018.88% |
| Neuland Laboratories Limited | 15.58 Billion INR | -159.924% |
| Morepen Laboratories Limited | 17.01 Billion INR | -138.035% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -2524.252% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -999.072% |